|
Table 1: characteristics of patients with macrocytosis, acute leukemia and bone marrow failure |
||||||||||||
|
Patient
|
Diagnosis |
Age |
Gender |
Wbc /mm3 |
Neut /mm3 |
Hgb gr/dl |
MCV |
Plt /mm3 |
Physical examination |
LFT |
TFT |
B12-folat |
|
1 |
AML M0 |
8 |
Male |
41.990 |
8100 |
7,1 |
99 |
24.000 |
HSM |
N |
- |
N |
|
2 |
AML M6-DS |
2 |
Female |
12.980 |
1200 |
5,6 |
93 |
50.000 |
HSM |
N |
N |
N |
|
3 |
ALL |
11 |
Female |
44.780 |
440 |
5,4 |
94 |
14.000 |
HSM-LAP |
N |
- |
N |
|
4 |
ALL |
4 |
Male |
8270 |
180 |
7,5 |
89 |
24.000 |
HSM-LAP |
N |
N |
N |
|
5 |
ALL |
15 |
Male |
12.290 |
290 |
3,7 |
94 |
6000 |
HSM-LAP |
N |
N |
N |
|
6 |
ALL |
8 |
Female |
7670 |
1160 |
7,3 |
93 |
263.000 |
HSM-LAP |
N |
N |
N |
|
7 |
ALL |
4 |
Male |
7470 |
210 |
7,2 |
101 |
171.000 |
HSM-LAP |
N |
- |
- |
|
8 |
ALL |
6 |
Female |
12.690 |
260 |
7,3 |
90 |
26.000 |
HSM-LAP |
N |
- |
- |
|
9 |
ALL |
10 |
Male |
3920 |
270 |
6,6 |
94 |
67.000 |
HSM |
N |
N |
- |
|
10 |
ALL |
3 |
Female |
3320 |
600 |
11,4 |
89 |
193.000 |
HSM |
2 fold increase |
N |
N |
|
11 |
ALL |
7 |
Male |
39.630 |
540 |
6,6 |
94 |
34.000 |
HSM-LAP |
N |
- |
N |
|
12 |
ALL |
12 |
Female |
57.980 |
1370 |
3,4 |
107 |
67.000 |
HSM-LAP |
N |
N |
N |
|
13 |
ALL-DS |
6 |
Female |
26.850 |
880 |
5,5 |
102 |
25.000 |
HSM-LAP |
N |
N |
N |
|
14 |
FAA |
11 |
Female |
1860 |
220 |
8,5 |
98 |
38.000 |
GR, Cafe-au-lait spots |
N |
N |
N |
|
15 |
FAA |
5 |
Male |
3810 |
330 |
8,2 |
94 |
26.000 |
GR, Cafe-au-lait spots |
N |
N |
N |
|
16 |
FAA |
4 |
Male |
5710 |
1180 |
12 |
96 |
144.000 |
GR |
N |
N |
N |
|
17 |
FAA |
5 |
Male |
4020 |
2030 |
12,2 |
93 |
74.000 |
GR, Cafe-au-lait spots |
N |
N |
N |
|
18 |
FAA |
5 Month |
Male |
9820 |
3560 |
5,4 |
101 |
323.000 |
microcephaly |
N |
N |
N |
|
19 |
FAA |
6 |
Female |
4320 |
1840 |
11,7 |
96 |
26.000 |
GR, Cafe-au-lait spots |
N |
N |
N |
|
20 |
FAA |
2 |
Female |
3330 |
1340 |
10,2 |
90 |
65.000 |
GR, Cafe-au-lait spots |
N |
N |
N |
|
21 |
AA |
14 |
Female |
2190 |
470 |
8,2 |
100 |
32.000 |
- |
N |
N |
N |
|
22 |
DBA |
2 |
Male |
5260 |
1520 |
7,5 |
103 |
462.000 |
GR |
N |
N |
N |
|
23 |
DBA |
1,5 |
Female |
9920 |
2820 |
6 |
89 |
446.000 |
- |
N |
N |
N |
|
24 |
CDA |
13 |
Female |
4740 |
3470 |
2,5 |
104 |
240.000 |
- |
N |
N |
B12: 146 |
|
25 |
MFS-AML M7-DS |
11 Month |
Male |
3170 |
890 |
5 |
94 |
17.000 |
HSM |
N |
N Treated for hypothyroidism |
N |
|
Wbc: White blood cell count, neut: neutrophil count, hgb: hemoglobin, plt: thrombocyte count, MCV: Mean corpusculer volume, LFT: liver function tests, TFT:Thyroid function tests, AML: acute myeloid leukemia, ALL: acute lymphoid leukemia, FAA: Fanconi aplastic anemia, AA: aplastic anemia, DBA: Diamond–Blackfan anemia, CDA: congenital dysery thropoetic anemia, MFS: myelofibrozis, DS: Down syndrome, HSM: hepatosplenomegaly, LAP: lymphadenopathy, GR: Growth retardation |
||||||||||||